People

MD, Icahn School of Medicine at Mount Sinai
BA, Sociology & Anthropology, Political Science, Swarthmore College

Opioid use disorder treatment in primary care and hospital settings, Innovative care delivery of hepatitis C and opioid use disorder treatment for people who use drugs, Substance use medical education

Linda Wang is Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS). She received her BA from Swarthmore College in 2009 and her MD from the Icahn School of Medicine at Mount Sinai. She trained in Primary Care and Social Internal Medicine Residency Program at Montefiore/Einstein, where she also served as Chief Resident. She is a provider at the REACH Program, where she provides primary care, substance use treatment, and harm reduction to people who use drugs. She also directs its Buprenorphine Nurse Care Manager Program and co-leads the REACH-IN initiative at Mount Sinai Hospital to initiate buprenorphine in hospitalized patients with opioid use disorder. Her research interests include buprenorphine treatment in primary care and hospital settings and substance use education for undergraduate and graduate medical education. She is an active medical educator and serves as Clerkship Director for the Interclerkship Ambulatory Care Track, a longitudinal integrated clerkship for select third-year medical students at ISMMS. She also directs a longitudinal three-year substance use curriculum for the Mount Sinai Hospital Internal Medicine Residency Program.

Recent

Dr. Wang's MyBibliography Profile

Telehealth Services Are Expanding OUD Medication Access — For Some

Filter Magazine

Linda Wang quoted on changes to being able to provide buprenorphine treatment via telehealth during the COVID-19 pandemic.

Biden Is Opposing a Promising Step Toward Buprenorphine Deregulation

Filter Magazine

Linda Wang wrote about the Biden administration's plans to obstruct the "X-waiver" requirement, which would expand the capacity for physicians to prescribe buprenorphine.